My Profile

Search abstracts

Lewis Sheiner


2017
Budapest, Hungary



2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain
   Program
   Organisers
   Abstracts
   Participants

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
KÝbenhavn, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland

Printable version

 

Tuesday June 10

 

18.30-20.00 Registration at the Cruise Terminal
       
20.30-22.30 Welcome reception at the Santísima Trinidad located in front of Hotel Melia
       

 

Wednesday June 11

 

08:00-08:45 Registration
       
08:45-09:00 Welcome and Introduction
       
09:00-10:20 OrBiTo and Mechanistic absorption modelling

Chair: Leon Aarons and Panos Macheras

09:00-09:40 Amin Rostami-Hodjegan OrBiTo - translating mechanistic knowledge on absorption into predictive models
09:40-10:00 Benjamin Guiastrennec Mechanism-based modelling of gastric emptying and bile release in response to caloric intake
10:00-10:20 Andrés Olivares-Morales An in silico physiologically-based pharmacokinetic (PBPK) study of the impact of the drug release rate on oral absorption, gut wall metabolism and relative bioavailability
       
10:20-11:50 Coffee break, Poster and Software session I
  Posters in Group I (with poster numbers starting with I-) are accompanied by their presenter
       
11:50-12:40 Facilitating Modelling and Simulation

Chair: Charlotte Kloft

11:50-12:10 Kapil Gadkar Development of Virtual Population for a Quantitative Systems Pharmacology model
12:10-12:30 Maciej Swat PharmML 1.0 – An Exchange Standard for Models in Pharmacometrics
12:30-12:40 Marc Gastonguay Proposal for a Web-Based Open Pharmacometrics Curriculum
       
12:40-14:10 Lunch
       
14:10-15:10 Model-based individualisation

Chair: Nick Holford

14:10-14:50 Pierre Marquet Implementing model-based individualization in the clinic
14:50-15:10 Núria Buil Bruna A step forward toward personalised medicine in oncology: Population modelling for the early prediction of disease progression using biomarkers
       
15:10-16:30 Tea break, Poster and Software session II
  Posters in Group II (with poster numbers starting with II-) are accompanied by their presenter
       
16:30-17:50 Drug/Disease modeling

Chair: Oscar Della Pasqua

16:30-16:50 Julia Korell Application of a model based longitudinal network meta-analysis of FEV1 in COPD trials in clinical drug development
16:50-17:10 Sebastian Weber Bayesian Drug Disease Model with Stan - Using published longitudinal data summaries in population models
17:10-17:30 Angelica Quartino An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer's Disease
17:30-17:50 Yaming Hang Pharmacokinetic and Pharmacodynamic Analysis Longitudinal Gd-Enhanced Lesion Count in Subjects with Relapsing Remitting Multiple Sclerosis Treated with Peginterferon beta-1a
       

 

Thursday June 12

 

08:45-10:05 Lewis Sheiner Student Session

Chair: Emmanuelle Comets, Joachim Grevel and Panos Macheras

08:45-09:10 Thi Huyen Tram Nguyen Handling data below the quantification limit in viral kinetic modeling for model evaluation and prediction of treatment outcome
09:10-09:35 Nikolaos Tsamandouras Development of population based approaches to describe the complex pharmacokinetics of simvastatin in different individuals. Bridging the gap between population and physiologically based pharmacokinetic modelling
09:35-10:00 Mélanie Wilbaux A dynamic K-PD joint model for the kinetics of CTC (Circulating Tumor Cell) count and PSA concentration during treatment in metastatic castration-resistant prostate cancer
10.00-10.05 Presentation of Lewis Sheiner student session awards
       
10:05-11:30 Coffee break, Poster and Software session I
  Posters in Group III (with poster numbers starting with III-) are accompanied by their presenter
       
11:30-12:50 Regulators and EFPIA initiatives for Modeling Informed Drug Discovery and Development (MID3)

Chair: Dinesh Dealwis and Marylore Chenel

11:30-11:50 Scott Marshall Proposed Modelling and Simulation good practices: Progress post EMA / EFPIA M&S workshop
11:50-12:15 Terry Shepard How European Regulators are Facilitating the Use of Modelling and Simulation: MSWG History, Activity and Future
12:15-12:35 Efthymios Manolis EMA qualification of novel methodologies: are we ready for M&S?
12.35-12.50 Panel discussion
       
12:50-14:15 Lunch
       
14:15-15:15 Regulators and EFPIA initiatives for Modeling Informed Drug Discovery and Development (MID3) continued

Chair: Mick Looby and Dinesh Dealwis

14:15-14:40 Bjoern Bornkamp The MCP-Mod methodology – A statistical methodology for dose-response modelling
14:40-15:15 Vikram Sinha The role of MBDD in drug development - is it time to repaint the canvas?
       
15:15-16:40 Tea break, Poster and Software session IV
  Posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter
       
16:40-17:20 Pharmacometric models for dose-finding and cost effectiveness

Chair: Lena Friberg

16:40-17:00 Camille Vong In silico comparison of MTD determination in a phase I dose-finding framework
17:00-17:20 Coen van Hasselt Towards early integrated mechanism-based prediction of clinical outcome and cost-effectiveness in castration-resistant prostate cancer
       

 

Friday June 13

 

09:00-10:00 Stuart Beal Methodology Session

Chair: France Mentré

09:00-09:20 Edouard Ollier Group comparison with fused lasso penalized likelihood: an alternative to test based methods
09:20-09:40 Elin Svensson Prediction of pharmacokinetic interactions for drugs with a long half-life – evidence for the need of model-based analysis
09:40-10:00 Yasunori Aoki Averaged Model Based Decision Making for Dose Selection Studies
       
10.00-10.05 Preview of PAGE 2015
       
10:00-10:40 Coffee break and Software session
       
10:50-12:10 Modelling in oncology

Chair: René Bruno

10:50-11:10 Sharon Hori Modeling cancer blood biomarker dynamics in relation to tumor growth
11:10-11:30 Rik de Greef Modeling of tumor size reduction patterns in advanced melanoma under treatment with MK-3475, a potent antibody against PD-1
11:30-11:50 Pauline Mazzocco A mixed-effect modeling framework to personalize treatment of low-grade glioma patients
11:50-12:10 Nick Holford Power and Type 1 Error of Tumour Size Metrics Used to Predict Survival
       
12.10-12.20 Closing remarks
       
12:20-12:40 Audience Input for the PAGE 2015 Program